<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.0.37">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>cid-review</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="CID review_files/libs/clipboard/clipboard.min.js"></script>
<script src="CID review_files/libs/quarto-html/quarto.js"></script>
<script src="CID review_files/libs/quarto-html/popper.min.js"></script>
<script src="CID review_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="CID review_files/libs/quarto-html/anchor.min.js"></script>
<link href="CID review_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="CID review_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="CID review_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="CID review_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="CID review_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">



<section id="the-pharmacological-basis-of-mucormycosis-therapy" class="level1">
<h1>The Pharmacological Basis of Mucormycosis Therapy</h1>
<p>Russell E. Lewis, Pharm.D.<sup>1</sup></p>
<p><sup>1</sup>Associate Professor, Infectious Diseases Department of Molecular Medicine, University of Padua , Padua, Italy</p>
<section id="introduction" class="level2">
<h2 class="anchored" data-anchor-id="introduction">Introduction</h2>
<p>Mucormycosis encompasses a spectrum of diseases caused by fungi in the order Mucorales that have a predisposition for causing aggressive, life-threatening pneumonia or rhino-orbital- cerebral infection in the severely immunocompromised, transplant or diabetic patients. Survival from these infections often depends on reversal of underlying predisposing metabolic or immunosuppressive conditions, surgical resection of infected tissue, and the timely administration of effective antifungal therapy. <span class="citation" data-cites="Chamilos2008503 jeong2015">[<a href="#ref-Chamilos2008503" role="doc-biblioref">1</a>,<a href="#ref-jeong2015" role="doc-biblioref"><strong>jeong2015?</strong></a>]</span>. Unfortunately, limited diagnostic tools and effective treatment options contributes to the high mortality associated with invasive mucormycosis. These challenges recently prompted the World Health Organization (WHO) to classify invasive mucormycosis as a fungal pathogen of “High Priority” for further research and development needs.</p>
<p>Amphotericin B is the long-standing drug of choice for mucormycosis <span class="citation" data-cites="cornely_etal19a">[<a href="#ref-cornely_etal19a" role="doc-biblioref">2</a>]</span>with most clinicians favouring administration of the less-nephrotoxic liposomal amphotericin B formulation at higher-doses (5-10 mg/kg/day) to rapidly load target tissues such as the lung and brain with amphotericin B to slow fungal tissue invasion and dissemination into these <span class="citation" data-cites="groll_etal19">[<a href="#ref-groll_etal19" role="doc-biblioref">3</a>]</span>. Patients with lack of clinical response or intolerance to amphotericin B may be switched to posaconazole or isavuconazole, or transitioned to oral formulations of these triazoles once infection has stabilized to complete therapy<span class="citation" data-cites="kontoyiannis_lewis11 cornely_etal19a">[<a href="#ref-cornely_etal19a" role="doc-biblioref">2</a>,<a href="#ref-kontoyiannis_lewis11" role="doc-biblioref">4</a>]</span>. Yet, the treatment of mucormycosis is still limited by the lack of effective treatment alternatives who cannot tolerate front-line therapies because of toxicities, drug interactions, or are infected with multidrug-resistant strains [ ]</p>
<p>In the previous monograph published from the First International Henry Schueler Supplement on Mucormycosis <span class="citation" data-cites="lewis_etal12">[<a href="#ref-lewis_etal12" role="doc-biblioref">5</a>]</span>, we examined how antifungal pharmacology and resistance differs for Mucorales versus more common <em>Aspergillus</em> infections. Since the publication of this monograph, new data has been published on Mucorales species-specific susceptibility profiles, triazole pharmacokinetic/pharmacodynamics (PK/PD), and the antifungal pipeline has grown (?) with several possible new therapeutic classes that may have a role for refractory infections. In this monograph, we will review the pharmacological basis for antifungal therapy in mucormycosis with a particular focus on new data published in the last 5-10 years that may shape future treatment strategies for this devastating infection.</p>
</section>
<section id="pharmacodynamic-challenges" class="level2">
<h2 class="anchored" data-anchor-id="pharmacodynamic-challenges">Pharmacodynamic challenges</h2>
<section id="in-vitro-susceptibility" class="level3">
<h3 class="anchored" data-anchor-id="in-vitro-susceptibility">In vitro susceptibility</h3>
<p>Table 1. In vitro susceptibility profiles for common Mucorales spp.</p>
<table class="table">
<colgroup>
<col style="width: 20%">
<col style="width: 20%">
<col style="width: 20%">
<col style="width: 20%">
<col style="width: 20%">
</colgroup>
<thead>
<tr class="header">
<th>Species</th>
<th>Amphotericin B</th>
<th>Itraconazole</th>
<th>Posaconazole</th>
<th>Isavuconazole</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>L. corymbifera</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>M. cicinellloides</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>R. arhizus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>R. microsporus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>M.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<section id="section" class="level4">
<h4 class="anchored" data-anchor-id="section"></h4>
<p>Breakpoints versus ECVs - Can we assume amphotericin B susceptibility ? - Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, et al.&nbsp;Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrobial agents and chemotherapy [Internet]. 2015 Mar;59(3):1745–50. Available from: http://dx.doi.org/10.1128/AAC.04435-14 - Do MICs predict outcome? - Lamoth F, Damonti L, Alexander BD. Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections. Journal of clinical microbiology [Internet]. 2016 Jun;54(6):1638–40. Available from: http://dx.doi.org/10.1128/JCM.00318-16 - Species-specific susceptibility-especially important for triazoles? - Wagner L, de Hoog S, Alastruey-Izquierdo A, Voigt K, Kurzai O, Walther G. A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles. Antimicrobial agents and chemotherapy [Internet]. 2019 Aug;63(8). Available from: http://dx.doi.org/10.1128/AAC.00653-19 - Media effects on Rhizopus virulence ## Pharmacokinetic challenges ## Treatment window-angioinvasion and tissue necrosis - Consider new figure - Old versus new: homogized tissue versus MALDI-MSI imaging - Penetration of drug into anatomically-privlidges sites - Intracellular antifungal activity insice macrophages and granulomas ## Integrating PK/PD concepts ### The Complex pharmacokinetics of liposomal AMB - feasibility of dose escalation to improve outcomes ### Triazole antifungals - Feasibility of dosage escalation to improve outcomes ### New hope from the antifungal pipeline? - In vitro vs.&nbsp;in vivo correlation - Combination therapy ## Summary - maturation of antifungal susceptibility testing - limited PK/PD basis for current antifungal dosing - The dire need for clinically-reliable biomarkers - Current limitations of antifungals in terms of complecx PK, toxicity, drug interactions - No phamracometrics/dosign guidance</p>
</section>
</section>
</section>
<section id="references" class="level2 unnumbered">


</section>
</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body" role="doc-bibliography">
<div id="ref-Chamilos2008503" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Chamilos G, Lewis RE, Kontoyiannis DP. <a href="https://doi.org/10.1086/590004">Delaying amphotericin <span class="nocase">B-based</span> frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis</a>. Clinical Infectious Diseases <strong>2008</strong>; 47:503–509. </div>
</div>
<div id="ref-cornely_etal19a" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. <a href="https://doi.org/10.1016/S1473-3099(19)30312-3">Global guideline for the diagnosis and management of mucormycosis: An initiative of the <span>European Confederation</span> of <span>Medical Mycology</span> in cooperation with the <span>Mycoses Study Group Education</span> and <span>Research Consortium</span></a>. The Lancet infectious diseases <strong>2019</strong>; 19:e405–e421. </div>
</div>
<div id="ref-groll_etal19" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. <a href="https://doi.org/10.1093/cid/ciz076">Clinical <span>Pharmacokinetics</span>, <span>Pharmacodynamics</span>, <span>Safety</span> and <span>Efficacy</span> of <span>Liposomal Amphotericin B</span></a>. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America <strong>2019</strong>; 68:S260–S274. </div>
</div>
<div id="ref-kontoyiannis_lewis11" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Kontoyiannis DP, Lewis RE. <a href="https://doi.org/10.1182/blood-2011-03-316430">How <span>I</span> treat mucormycosis</a>. Blood <strong>2011</strong>; 118:1216–1224. </div>
</div>
<div id="ref-lewis_etal12" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Lewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. <a href="https://doi.org/10.1093/cid/cir884">How does antifungal pharmacology differ for mucormycosis versus aspergillosis?</a> Clinical infectious diseases: an official publication of the Infectious Diseases Society of America <strong>2012</strong>; 54 Suppl 1:S67–S72. </div>
</div>
</div></section></div></main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    setTimeout(function() {
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      let href = ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const cites = ref.parentNode.getAttribute('data-cites').split(' ');
    tippyHover(ref, function() {
      var popup = window.document.createElement('div');
      cites.forEach(function(cite) {
        var citeDiv = window.document.createElement('div');
        citeDiv.classList.add('hanging-indent');
        citeDiv.classList.add('csl-entry');
        var biblioDiv = window.document.getElementById('ref-' + cite);
        if (biblioDiv) {
          citeDiv.innerHTML = biblioDiv.innerHTML;
        }
        popup.appendChild(citeDiv);
      });
      return popup.innerHTML;
    });
  }
});
</script>
</div> <!-- /content -->



</body></html>